GlassScriptPhysician profile
Kunjal Modi
NPI 1548689904
$23,953.77
in general payments reported to CMS, 2019-2025
24 companies · $9,957 in 2025
The $9,957 reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $238 · 2021: $1,088 · 2022: $1,219 · 2023: $5,223 · 2024: $5,986 · 2025: $9,957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,000 · Honoraria: $6,600 · Food and Beverage: $6,566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,000.00 |
| Honoraria | $6,600.00 |
| Food and Beverage | $6,565.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $8,834.45 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| New World Medical,INC. | $7,361.50 | 2023-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Bausch & Lomb Americas INC. | $1,520.96 | 2022-2025 | Envista Mx60 Iol, Vyzulta, Prolensa |
| Abbvie INC. | $1,060.74 | 2022-2025 | |
| Allergan, INC. | $1,027.87 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $949.02 | 2021-2025 | Cequa |
| Biotissue Holdings INC. | $906.65 | 2021-2025 | |
| Tarsus Pharmaceuticals, INC. | $364.33 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $305.19 | 2024-2025 | Idose, Idosetr, Istent Trabecular Micro-Bypass System Model Is3 |
| Aerie Pharmaceuticals, INC. | $293.23 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $237.43 | 2023-2025 | Catalys System, Tecnis Simplicity, Tecnis Iol |
| Alcon Vision LLC | $186.43 | 2022-2025 | Clareon, Hydrus Microstent, Clareon Panoptix Pro |
| Kala Pharmaceuticals, INC. | $146.72 | 2020-2022 | |
| Ocular Therapeutix, INC. | $143.26 | 2022-2025 | Dextenza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $125.93 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $107.63 | 2023 | Oxervate |
| Travere Therapeutics, INC. | $95.22 | 2021-2023 | Cholbam |
| Oyster Point Pharma, INC. | $79.74 | 2022-2025 | Tyrvaya, Ryzumvi |
| Eyevance Pharmaceuticals LLC | $57.59 | 2022 | |
| Mallinckrodt Hospital Products INC. | $37.19 | 2024-2025 | Acthar |
| Hologic Sales and Service, LLC | $35.69 | 2025 | Novasure, Fluent Fluid Management System, Myosure Tissue Removal Device |
| Sandoz INC. | $34.40 | 2024 | Cimerli |
| Coherus Oncology, INC. | $28.13 | 2023 | |
| Genentech USA, INC. | $14.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kunjal Modi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.